Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

ORAGRAFIN CALCIUM

IPODATE CALCIUM

Standard Dose
3GM/PACKET
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Discontinued
Summary

Approval overview ORAGRAFIN CALCIUM is listed in Drugs@FDA under application 012968 (NDA).

Review priority: PRIORITY Marketing status: Discontinued Active ingredient IPODATE CALCIUM Form and strength GRANULE;ORAL - 3GM/PACKET Sponsor BRACCO Submission history Latest submission status date: 1991-05-06 00:00:00.

Structured Monograph

Clinical summary

Approval overview ORAGRAFIN CALCIUM is listed in Drugs@FDA under application 012968 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient IPODATE CALCIUM Form and strength GRANULE;ORAL - 3GM/PACKET Sponsor BRACCO Submission history Latest submission status date: 1991-05-06 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.